Naldemedine (trade name: Rizmoic) has been approved in Germany since February 2019 for the treatment of opioid-induced constipation in adults. It is a treatment option for people who have already had treatment with a laxative.
Severe, chronic pain caused by cancer or another serious, chronic disease is often treated with painkillers called opioids.
One typical side effect of opioid painkillers is constipation: Opioids attach to certain receptors in the bowel and reduce the movement of the bowel, causing stool to move more slowly through the bowel. Doctors refer to this as opioid-induced constipation. Over the course of several weeks, this constipation can become a major problem for patients.
Naldemedine prevents the opioid painkillers from attaching to the receptors in the bowel. This is supposed to relieve the constipation.
Naldemedine is taken once daily in tablet form (200 μg naldemedine), ideally always at the same time of day.
The treatment is stopped when opioid painkillers are no longer used.
Various medications can be used to treat constipation, as well as medical products that are supposed to change the composition of the stool, for instance. If one of these treatments is not effective enough, various alternatives can be tried out. If it is not possible to use any of these treatments, the drugs methylnaltrexone, prucalopride or naloxegel can be used.
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of naldemedine compared to the standard treatments for opioid-induced constipation in people who have already used other laxatives.
But the manufacturer didn’t provide any suitable data with which to do the assessment.
This information summarizes the main results of a review by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The IQWiG review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of naldemedine (Rizmoic).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Naldemedine (opioid-induced constipation) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A20-45. August 13, 2020. (IQWiG reports; Volume 958).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.